Question: As of August 2016, what was the market capitalisation of the company that developed the drug Losmapimod?

full_context: Document 1: London Stock Exchange: The London Stock Exchange (LSE) is a stock exchange located in the City of London, England. s of 2014 , the Exchange had a market capitalisation of US$6.06 trillion (short scale), making it the third-largest stock exchange in the world by this measurement (the largest in Europe, ahead of Euronext). The Exchange was founded in 1801 and its current premises are situated in Paternoster Square close to St Paul's Cathedral in the City of London. The Exchange is part of the London Stock Exchange Group.
Document 2: Hong Kong Stock Exchange: The Stock Exchange of Hong Kong Limited (SEHK) is a stock exchange located in Hong Kong. It is East Asia's and Asia's third largest stock exchange in terms of market capitalization behind the Tokyo Stock Exchange and Shanghai Stock Exchange, and the sixth largest in the world before Euronext. As of 31 October 2016, SEHK had 1,955 listed companies, 989 of which are from mainland China, 856 from Hong Kong and 110 from abroad (e.g. Taiwan, Malaysia, United States, Singapore, etc.) Hong Kong Exchanges and Clearing owns SEHK and is itself listed on SEHK.
Document 3: Osilodrostat: Osilodrostat (INN, USAN) (developmental code name LCI-699) is an orally active, non-steroidal corticosteroid biosynthesis inhibitor which is under development by Novartis for the treatment of Cushing's syndrome and pituitary hypersecretion (a specific subtype of Cushing's syndrome). It specifically acts as a potent and selective inhibitor of aldosterone synthase (CYP11B2) and at higher dosages of 11β-hydroxylase (CYP11B1). The drug was also under development for the treatment of heart failure, hypertension, and solid tumors, but development was discontinued for these indications. As of 2017, osilodrostat is in phase III and phase II clinical trials for treatment of pituitary ACTH hypersecretion and Cushing's syndrome, respectively.
Document 4: GlaxoSmithKline Pharmaceuticals Ltd: GlaxoSmithKline Pharmaceuticals Ltd ( ) is an Indian subsidiary of GlaxoSmithKline plc, one of the world's leading research based pharmaceutical and healthcare companies. It is one of the oldest pharmaceuticals companies in India. It product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease and respiratory diseases. It also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer and others.
Document 5: FTSE 350 Index: The FTSE 350 Index index is a market capitalization weighted stock market index incorporating the largest 350 companies by capitalization which have their primary listing on the London Stock Exchange. It is a combination of the FTSE 100 Index of the largest 100 companies and the FTSE 250 Index of the next largest 250. The index is maintained by FTSE Russell, a subsidiary of the London Stock Exchange Group. See the articles about those indices for lists of the constituents of the FTSE 350.
Document 6: Toronto Stock Exchange: Toronto Stock Exchange (often abbreviated as TSX) is one of the world's largest stock exchanges. It is the ninth largest exchange in the world by market capitalization. Based in Toronto, it is owned by and operated as a subsidiary of the TMX Group for the trading of senior equities. A broad range of businesses from Canada and abroad are represented on the exchange. In addition to conventional securities, the exchange lists various exchange-traded funds, split share corporations, income trusts and investment funds. More mining and oil and gas companies are listed on Toronto Stock Exchange than any other stock exchange.
Document 7: Gelsemine: Gelsemine (CHNO) is an indole alkaloid isolated from flowering plants of the genus "Gelsemium", a plant native to the subtropical and tropical Americas, and southeast Asia, and is a highly toxic compound that acts as a paralytic, exposure to which can result in death. It has generally potent activity as an agonist of the mammalian glycine receptor, the activation of which leads to an inhibitory postsynaptic potential in neurons following chloride ion influx, and systemically, to muscle relaxation of varying intensity and deleterious effect. Despite its danger and toxicity, recent pharmacological research has suggested that the biological activities of this compound may offer opportunities for developing treatments related to xenobiotic- or diet-induced oxidative stress, and of anxiety and other conditions, with ongoing research including attempts to identify safer derivatives and analogs to make use of gelsemine's beneficial effects.
Document 8: Safinamide: Safinamide (INN; brand name Xadago) is a drug used as an add-on treatment for Parkinson's disease during "off" episodes; it has multiple modes of action, including the inhibition of monoamine oxidase B.
Document 9: GlaxoSmithKline: The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. As of August 2016 it had a market capitalisation of £81 billion (around $107 billion), the fourth largest on the London Stock Exchange. It has a secondary listing on the New York Stock Exchange.
Document 10: Biological response modifiers: Biological response modifiers (BRMs) are substances that modify immune responses. They can be both endogenous (produced naturally within the body) and exogenous (as pharmaceutical drugs), and they can either enhance an immune response or suppress it. Some of these substances arouse the body's response to an infection, and others can keep the response from becoming excessive. Thus they serve as immunomodulators in immunotherapy (therapy that makes use of immune responses), which can be helpful in treating cancer (where targeted therapy often relies on the immune system being used to attack cancer cells) and in treating autoimmune diseases (in which the immune system attacks the self), such as some kinds of arthritis and dermatitis. Most BRMs are biopharmaceuticals (biologics), including monoclonal antibodies, interleukin 2, interferons, and various types of colony-stimulating factors (e.g., CSF, GM-CSF, G-CSF). "Immunotherapy makes use of BRMs to "enhance" the activity of the immune system to increase the body's natural defense mechanisms against cancer", whereas BRMs for rheumatoid arthritis aim to reduce inflammation.
Document 11: Losmapimod: Losmapimod (GW856553X) is a drug developed by GlaxoSmithKline which acts as a selective inhibitor of the enzyme family known as p38 mitogen-activated protein kinases.
Document 12: Difenamizole: Difenamizole (INN) (brand name Pasalin; former developmental code name AP-14) is a nonsteroidal anti-inflammatory drug (NSAID) and analgesic of the pyrazolone group related to metamizole. It has monoaminergic properties, including inhibition of monoamine oxidase, augmentation of pargyline-induced elevation of striatal dopamine levels, inhibition of K-induced striatal dopamine release, and inhibition of the reuptake of dopamine.
Document 13: Shire (pharmaceutical company): Shire Plc is a Jersey-registered, Irish-headquartered global specialty biopharmaceutical company. Originating in the United Kingdom with an operational base in the United States, its brands and products include Vyvanse, Lialda, and Adderall XR. Shire has its primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. Shire has a secondary listing on NASDAQ.
Document 14: Protein phosphatase: A protein phosphatase is a phosphatase enzyme that removes a phosphate group from the phosphorylated amino acid residue of its substrate protein. Protein phosphorylation is one of the most common forms of reversible protein posttranslational modification (PTM), with up to 30% of all proteins being phosphorylated at any given time. Protein kinases (PKs) are the effectors of phosphorylation and catalyse the transfer of a γ-phosphate from ATP to specific amino acids on proteins. Several hundred PKs exist in mammals and are classified into distinct super-families. Proteins are phosphorylated predominantly on Ser, Thr and Tyr residues, which account for 79.3, 16.9 and 3.8% respectively of the phosphoproteome, at least in mammals. In contrast, protein phosphatases (PPs) are the primary effectors of dephosphorylation and can be grouped into three main classes based on sequence, structure and catalytic function. The largest class of PPs is the phosphoprotein phosphatase (PPP) family comprising PP1, PP2A, PP2B, PP4, PP5, PP6 and PP7, and the protein phosphatase Mg- or Mn-dependent (PPM) family, composed primarily of PP2C. The protein Tyr phosphatase (PTP) super-family forms the second group, and the aspartate-based protein phosphatases the third. The protein pseudophosphatases form part of the larger phosphatase family, and in most cases are thought to be catalytically inert, instead functioning as phosphate-binding proteins, integrators of signalling or subcellular traps. Examples of membrane-spanning protein phosphatases containing both active (phosphatase) and inactive (pseudophosphatase) domains linked in tandem are known, conceptually similar to the kinase and pseudokinase domain polypeptide structure of the JAK pseudokinases. A complete comparative analysis of human phosphatases and pseudophosphatases has been completed by Manning and colleagues, forming a companion piece to the ground-breaking analysis of the human kinome, which encodes the complete set of ~536 human protein kinases.
Document 15: P57 (glycoside): P57 is an oxypregnane steroidal glycoside isolated from the African cactiform "Hoodia gordonii". P57 is thought to be the main active constituent from this plant that may be responsible for the possible appetite suppressant activity of Hoodia extracts.
ground_truth: £81 billion